We therefore investigated the changes in cellular viability as well as the expression of the ERα-responsive downstream gene, progesterone receptor (PGR), in ERα-negative MDA-MB-231 breast cancer cells with treatments of EGCG and TSA alone or together. The gene discussed is ESR1; the disease is breast carcinoma.